Navigation Links
IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements
Date:2/20/2008

IRVINE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it received notification from The NASDAQ Stock Market that the Company has regained compliance with NASDAQ Marketplace Rule 4450(a)(5), which requires listed companies to maintain a closing bid price of at least $1.00 per share.

On February 19, 2008, the closing price of the Company's common stock was $3.14 per share.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's ability to comply with the minimum bid price requirements under the NASDAQ Marketplace Rules. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to maintain a closing bid price of $1.00 per share or higher and risks relating to the Company's ability to comply with other NASDAQ requirements. Other risks affecting the Company and its drug development programs are more fully discussed in the Company's Quarterly Report on
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
2. Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism
3. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
4. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
5. Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management
6. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
7. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
8. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
9. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
10. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
11. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... from Boston University School of Medicine (BUSM) and ... who received care through BMC,s Violence Intervention Advocacy ... emotional and social needs of violently injured youthswere ... experienced life changing behaviors through connections to caring, ... and hope. These findings are reported in the ...
(Date:7/22/2014)... from the Sloan-Kettering Institute for Cancer Research in New ... Schools of Medicine and Dentistry have completed research which ... how some cells in the brain and nervous system ... published in the prestigious journal Cancer Cell . ... a tumour suppressor called Merlin. , The results ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 BlogHer, ... for women, this year celebrates its tenth anniversary where ... Thousands of attendees, including community leaders from the new ... representing every consumer vertical, will converge in San Jose ... conversation, and a “selfiebration” of social technology. , ...
(Date:7/22/2014)... SWAMP , the first ... has completed an upgrade that significantly improves the ... with a $23.4 million grant from the ... (DHS S&T), the Software Assurance Marketplace (SWAMP) ... to assess the security of their software, but ...
(Date:7/22/2014)... New study findings released today confirm ... patient-centered program is working to improve the coordination of ... the largest to date and includes more than 200,000 ... that focuses on delivering better quality outcomes, a better ... , “Our most recent study results clearly demonstrate the ...
Breaking Medicine News(10 mins):Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Research brings us nearer to understanding how neuro cells turn cancerous 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 3Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 4Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 2Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 3Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 4Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 5Health News:Horizon BCBSNJ’s 2013 Study Results Demonstrate Patient-centered Program Improves Patient Care and Lowers Costs 2Health News:Horizon BCBSNJ’s 2013 Study Results Demonstrate Patient-centered Program Improves Patient Care and Lowers Costs 3
... Global health organization PSI helps contestants spread HIV prevention ... Bahamas, Aug. 21 The Miss Universe contestants continued preparations for ... tossing water-filled condoms to test their strength and playing "Wild Fire ... The games are part of an HIV peer education workshop designed ...
... ... Mesothelioma Patients , ... Newton, MA (PRWEB) August 21, 2009 -- MesoRC.com, an online community and resource center ... diseases, provides an extra source of valuable information with the introduction of Twitter. The ...
... , , LOS ANGELES, Aug. ... the launch of Energy-X, a new lip balm that delivers an effective ... sweeteners. With zero calories, Energy-X provides the energy boost consumers want without ... "Energy-X is applied directly on the lips and is therefore ...
... , , , ... to a Benefit Concert, Dessert and Auction, featuring LA Collaboration, at ... , 1243 Artesia Blvd, Manhattan Beach, CA - (310) 372-4641 ... price of 1 tickets. , , The concert features ...
... treating a recurrent or residual brain aneurysm that was ... a multicenter study led by researchers at the University ... of 311 patients with coiled aneurysms who underwent retreatment ... death or permanent major disability was slightly over one ...
... , FRAMINGHAM, Mass. and SYDNEY, Aug. ... announced that HeartWare has surpassed 50 implants in the United States ... , , The 50th implant in the ... Houston, Texas by O.H. Frazier, MD a distinguished surgeon, scientist, and ...
Cached Medicine News:Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 2Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 3Health News:Mesothelioma Resource Center Enters Twitter World 2Health News:Energy-X Lip Balm Delivers Wake-Up Call to Consumers 2Health News:The Sensory Research Center (SRC) Offers 2 for 1 Tickets for Benefit Concert Supporting Autism, Down's Syndrome, Cerebral Palsy and Other Disabilities. 2Health News:Study finds low risk in treating previously coiled aneurysm 2Health News:Study finds low risk in treating previously coiled aneurysm 3Health News:HeartWare International Surpasses 50 Implants in the US 2Health News:HeartWare International Surpasses 50 Implants in the US 3
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
(Date:7/22/2014)... 22, 2014 The Intellectual ... , the world,s leading provider of intelligent ... Cortellis Clinical Trials Intelligence , its ... milestone with the documentation of more than ... with greater and quicker access to critical ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
...  InterMune, Inc. (NADSAQ: ITMN) today reported that ... its decision granting the additional benefit of ... of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  Esbriet,s ... (not quantifiable benefit)  in the rating system ...
... Pharma Holdings, Inc. (NYSE AMEX: CPHI ) ("China ... China, today announced financial results for the year ended December ... , Revenue increased 9% to $81.2 million in fiscal ... , Income from operations was $22.0 million in fiscal year ...
Cached Medicine Technology:Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 2Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 3Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 4Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 5Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 6China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 2China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 3China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 4China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 5China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 6China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 7China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 8China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 9China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 10China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 11China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 12
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple intuitive ...
... modified battery chargers are ... for GENIE blotters. They ... very specific voltages, giving ... laboratory power supplies. 110 ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Inquire...
Medicine Products: